Li Peng, PhD

Li Peng has over 15 years of industry experience in drug discovery and development. Since joining Palleon at its launch in 2016, she has led the invention of Palleon’s EAGLE, CONVERGENCE and HYDRA platforms and overseen research and early development, including discovery, pharmacology, toxicology, and CMC. Previously, Li worked at Medimmune/AstraZeneca for 10 years in roles of increasing responsibility, leading drug discovery programs and cross-functional project teams. She has published over 30 scientific papers and is an inventor on ~20 patents and patent applications. Li earned a B.S. in biology from Capital Normal University, Beijing, and a Ph.D. in biochemistry and molecular biology from the University of California, Davis.